Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease
Open Access
- 20 October 2012
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 35 (2), 264-270
- https://doi.org/10.1007/s11239-012-0821-8
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Fibrin Clot Structure and FunctionArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in menHaematologica, 2009
- Structure of fibrin: impact on clot stabilityJournal of Thrombosis and Haemostasis, 2007
- Plasma Homocysteine Affects Fibrin Clot Permeability and Resistance to Lysis in Human SubjectsArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery diseaseJournal of Thrombosis and Haemostasis, 2006
- TAFI activity in coronary artery disease: A contribution to the current discussion on TAFI assaysThrombosis and Haemostasis, 2006
- The effect of glycaemic control on fibrin network structure of type 2 diabetic subjectsThrombosis and Haemostasis, 2006
- Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complicationsBlood Coagulation & Fibrinolysis, 2003
- TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin ComplexPublished by Elsevier ,1996
- Fibrinogen as a Risk Factor for Stroke and Myocardial InfarctionNew England Journal of Medicine, 1984